Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia

Inclusion Criteria

• •1. Adult men or women, 18 years of age or older.
• •2. Meet DSM-IV criteria for Schizophrenia
• •3. Women of childbearing potential must test negative for pregnancy at the time of enrollment based on urine pregnancy test and agree to use a reliable method of birth control during the study.
• •4. Must be on a therapeutic dose of 1 or 2 atypical antipsychotic medications (examples but not limited to Clozapine Olanzapine, Risperidone, Ziprasidone, Aripiprazole, Seroquel) with no major dose changes for at least 4 weeks.
• •5. A minimum PANSS total score of 55 at baseline and a score of at least 4 (moderate) on the subscale of the PANSS (suspiciousness/persecution) at screening.
• •6. Have a Clinical Global Impressions-Severity (CGI-S) scale score of at least 4 (moderately ill) at baseline;
• •7. Must be able to communicate effectively with the investigator and study coordinator and have the ability to provide informed consent.
• •8. Must be able to use nasal spray
• •9. Must demonstrate an acceptable degree of compliance with medication and procedures in the opinion of the investigator.